A draft policy from the US National Institutes of Health says that multi-site clinical studies should use a single institutional review board, according to an agency press release.

When protections for research participants were established, NIH notes that most studies were conducted at one site. Now as many studies are taking place across a number of sites, multiple IRBs are used. This, the agency argues, is not efficient.